Skip to content
TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
$129.68M-15.4%$153.35M+8.5%$141.34M+9.3%$129.26M+4.8%$123.32M+56.1%
$27.19M+12.5%$24.18M+14.7%$21.08M+10.5%$19.07M+11.6%$17.09M+11.7%
$156.87M-11.6%$177.53M+9.3%$162.42M+9.5%$148.33M+5.6%$140.41M+48.9%
$156.87M-11.6%$177.53M+9.3%$162.42M+9.5%$148.33M+5.6%$140.41M+48.9%
-$156.87M+11.6%-$177.53M-9.3%-$162.42M-9.5%-$148.33M-5.6%-$140.41M-48.9%
$11.63M+3.6%$11.23M+1.9%$11.02M-2.9%$11.35M-12.3%$12.95M-6.3%
-$145.24M+12.7%-$166.31M-9.8%-$151.4M-10.5%-$136.98M-7.5%-$127.46M-58.4%
-$3.47+21.3%-$4.41-4.0%-$4.24-5.5%-$4.02-6.6%-$3.77-46.7%
-$3.47+21.3%-$4.41-4.0%-$4.24-5.5%-$4.02-6.6%-$3.77-46.7%
160.4M+7.5%149.3M+4.9%142.3M+6.2%134M+1.1%132.5M+7.2%
160.4M+7.5%149.3M+4.9%142.3M+6.2%134M+1.1%132.5M+7.2%
-$145.49M+12.4%-$166.08M-9.9%-$151.19M-10.4%-$137M-7.5%-$127.48M-58.0%
$11.63M+3.6%$11.23M+1.9%$11.02M-2.9%$11.35M-12.3%$12.95M-6.3%
$366.25K+319%$87.5K+145%$35.75K+117%
$366.25K+319%$87.5K+145%$35.75K+117%
-$156.87M+11.6%-$177.53M-9.3%-$162.42M-9.5%-$148.33M-5.6%-$140.41M-48.9%
-$159.7M+11.6%-$180.56M
-$159.7M+11.6%-$180.56M
-$156.87M+11.6%-$177.53M-9.3%-$162.42M-9.5%-$148.33M-5.6%-$140.41M-48.9%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Is ArriVent BioPharma, Inc. profitable?
ArriVent BioPharma, Inc. is not currently profitable: it reported a net loss of $145.2M over the trailing twelve months.
What is ArriVent BioPharma, Inc.'s earnings per share?
ArriVent BioPharma, Inc.'s diluted EPS over the trailing twelve months is $-3.47.
Where does ArriVent BioPharma, Inc.'s income statement data come from?
Every line is extracted from ArriVent BioPharma, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.